Directional modifications of resibufogenin by Mucor subtilissimus and Pseudomonas aeruginosa

Biocatalysis and Biotransformation

Volumn 21, Issue 3, 2003, Pages 141-143

  Zhan, Jixun ^a,b   Zhang, Yuanxing ^b   Liu, Wenhui ^a   Guo, Hongzhu ^a   Guo, Dean ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Dehydrogenation; Directional modifications; Hydroxylation; Mucor subtilissimus; Pseudomonas aeruginosa; Resibufogenin

Indexed keywords

DEHYDROGENATION; HYDROXYLATION; SUBSTRATES;

DIRECTIONAL MODIFICATION;

CHEMICAL MODIFICATION;

12 HYDROXYRESIBUFOGENIN; 12BETA HYDROXY 3 KETORESIBUFOGENIN; BUFOGENIN; CINOBUFAGIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM CULTURE; CHEMICAL MODIFICATION; DRUG HYDROXYLATION; DRUG STRUCTURE; DRUG TRANSFORMATION; HYDROGENATION; MUCOR; NONHUMAN; PSEUDOMONAS AERUGINOSA;

BACTERIA (MICROORGANISMS); MUCOR; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0141955988     PISSN: 10242422     EISSN: None     Source Type: Journal    
DOI: 10.1080/10242420310001597793     Document Type: Article

References (10)

1. Chen, Y., Xiang, J., Gu W. and Xu, M. (1998) "Chemical constituents of Bufo Siccus", China J. Chin. Materia Medica 23, 620-621.
2. Kamano, Y., Kotake A., Hashima, H., Inoue M., Morita, H., Takeya, K., Itokawa, H., Nandachi, N., Segawa, T., Yukita, A., et al. (1998) "Structure-cytotoxic activity relationship for the toad poison bufadienolides", Bioorg. Med. Chem. 6, 1103-1115.
3. Krenn, L. and Kopp, B. (1998) "Bufadienolides from animal and plant sources", Phytochemistry 48, 1-29.
4. Nogawa, T., Kamano, Y., Yamashita, A. and Pettit, G.R. (2001) "Isolation and structure of five new cancer cell growth inhibitory bufadienolides from traditional drug Chan' an Su", J. Nat. Prod. 64, 1148-1152.
5. Pamnani, M.B., Chen, S., Yuan, C.M. and Haddy, F.J. (1994) "Chronic blood pressure effects of bufalin, a sodium-potassium ATPase inhibitor, in rats", Hypertension 23(Suppl 1), 106-109.
6. Terness, P., Novolan, D., Dufter, C., Kopp, B. and Opelz G. (2001) "The T-cell suppressive effect of bufadienolides: Structural requirements for their immunoregulatory activity", Internat. Immunopharmacol. 1, 119-134.
7. Xie, J.T., Dey, L., Wu, J.A., Lowell, T.K. and Yuan, C.S. (2001) "Cardiac toxicity of resibufogenin: Electrophysiological evidence", Acta. Pharmacol. Sin. 22, 289-297.
8. Yuan, C., Manunta, P., Chen, S., Hamlyn, J.M., Haddy, F.J. and Pamnani, M.B. (1993) "Role of ouabain-like factors in hypertension: Effects of ouabain and certain endogenous ouabain-like factors in hypertension", J. Cardiovasc. Pharmacol. 22, S10-S12.
9. Zhan, J., Liu, W., Guo, H., Zhang, Y., Guo, D. (2003) Selective dehydrogenation of resibufogenin and cinobufagin at 3-OH by Pseudomonas aeruginosa. Enzyme Microb. Technol. 33, 29-32.
10. Zhang, L., Nakaya, K., Yoshida, T. and Kuroiwa, Y. (1992) "Induction by bufalin of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers", Cancer Res. 52, 4634-4641.